ATE481644T1 - Prognose des verlaufs einer krebserkrankung - Google Patents

Prognose des verlaufs einer krebserkrankung

Info

Publication number
ATE481644T1
ATE481644T1 AT04733219T AT04733219T ATE481644T1 AT E481644 T1 ATE481644 T1 AT E481644T1 AT 04733219 T AT04733219 T AT 04733219T AT 04733219 T AT04733219 T AT 04733219T AT E481644 T1 ATE481644 T1 AT E481644T1
Authority
AT
Austria
Prior art keywords
concentration
amount
protein
correlating
cancer
Prior art date
Application number
AT04733219T
Other languages
English (en)
Inventor
Sven Skog
Staffan Eriksson
Bernhard Tribukait
Qimin He
Original Assignee
Arocell Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arocell Ab filed Critical Arocell Ab
Application granted granted Critical
Publication of ATE481644T1 publication Critical patent/ATE481644T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT04733219T 2003-05-16 2004-05-14 Prognose des verlaufs einer krebserkrankung ATE481644T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47124503P 2003-05-16 2003-05-16
PCT/SE2004/000750 WO2004100760A1 (en) 2003-05-16 2004-05-14 Predicting cancer progression

Publications (1)

Publication Number Publication Date
ATE481644T1 true ATE481644T1 (de) 2010-10-15

Family

ID=33452434

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04733219T ATE481644T1 (de) 2003-05-16 2004-05-14 Prognose des verlaufs einer krebserkrankung

Country Status (7)

Country Link
US (4) US20070141650A1 (de)
EP (1) EP1627230B1 (de)
JP (1) JP4668180B2 (de)
AT (1) ATE481644T1 (de)
DE (1) DE602004029156D1 (de)
ES (1) ES2353014T3 (de)
WO (1) WO2004100760A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070141650A1 (en) * 2003-05-16 2007-06-21 Sven Skog Predicting cancer progression
ZA200707334B (en) * 2005-02-25 2009-02-25 Roennerbol Holding Ab A method and kit for determination of thymidine kinase activity and use thereof
WO2008142664A2 (en) * 2007-05-23 2008-11-27 Arocell Ab Exposed thymidine kinase 1 peptides, ligands and methods employing the same
US20160082032A1 (en) * 2013-05-17 2016-03-24 Taiho Pharmaceutical Co., Ltd. Therapeutic effect prediction method for colorectal cancer patient in whom expression of tk1 protein has increased
CN105980407B (zh) * 2013-12-19 2020-01-07 阿洛赛尔公司 单克隆抗tk1抗体
CA3031645A1 (en) * 2016-08-10 2018-02-15 Alertix Veterinary Diagnostics Ab Determination of non-human mammal tk1 protein levels
JP2021522192A (ja) * 2018-04-18 2021-08-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規抗チミジンキナーゼ抗体
CN110873711B (zh) * 2018-09-04 2022-02-22 华瑞同康生物技术（深圳）有限公司 一种基于全自动化学发光分析仪的血清tk1检测试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4317877A (en) * 1980-06-05 1982-03-02 Sloan Kettering Institute Process for detecting the presence of malignant and pre-malignant cells in humans
AU675872B2 (en) * 1993-08-06 1997-02-20 Brigham Young University Technology Transfer Office Monoclonal antibodies to thymidine kinase isozymes
SE9401380D0 (sv) * 1994-04-22 1994-04-22 Sven Skog Ny celltillväxt-relaterad peptid och användning därav
US6678669B2 (en) * 1996-02-09 2004-01-13 Adeza Biomedical Corporation Method for selecting medical and biochemical diagnostic tests using neural network-related applications
ATE352039T1 (de) 2002-07-27 2007-02-15 Diasorin Ab Verfahren zur bestimmung der aktivität von thymidinkinase-1 und dessen verwendung
US20070141650A1 (en) * 2003-05-16 2007-06-21 Sven Skog Predicting cancer progression

Also Published As

Publication number Publication date
DE602004029156D1 (de) 2010-10-28
US20170067900A1 (en) 2017-03-09
US20200124608A1 (en) 2020-04-23
ES2353014T3 (es) 2011-02-24
US20070141650A1 (en) 2007-06-21
JP4668180B2 (ja) 2011-04-13
WO2004100760A8 (en) 2005-02-03
WO2004100760A1 (en) 2004-11-25
EP1627230B1 (de) 2010-09-15
JP2006526156A (ja) 2006-11-16
US11959919B2 (en) 2024-04-16
US10551385B2 (en) 2020-02-04
US20100311081A1 (en) 2010-12-09
EP1627230A1 (de) 2006-02-22

Similar Documents

Publication Publication Date Title
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
MXPA05010827A (es) Determinacion de un peptido parcial de la region mid de la proadrenomedulina en fluidos biologicos para propositos de diagnostico, e inmunoensayos para la conduccion de una identificacion de este tipo.
NO20076656L (no) Forbedrede immunoassay metoder
DE59903915D1 (de) Verfahren zur frühen diagnose von carcinomen
NO20050775L (no) Fremgangsmater for identifisering av tumorer som responderer pa behandling med anti-ErbB2-antistoffer
EP2131198A3 (de) Messung der zirkulierenden therapeutischen Antikörper-, Antigen- und Antigen-/Antikörperkomplexe unter Verwendung enzymgekoppelter Immunadsorptionstests
WO2004058044A3 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
DE50306067D1 (de) Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
BRPI0210579B8 (pt) anticorpo e composição farmacêutica
MX2007006529A (es) Seleccionar pacientes para terapia con un inhibidor her.
WO2005010213A3 (en) Markers for detection of gastric cancer
EA201301072A1 (ru) Антитела против il-23p19 и их применение
ATE372784T1 (de) Rekombinante proteine, die epitope des humanen papillomavirus inseriert in einem adenylatecyclase protein oder in dessen fragmenten tragen, und deren terapeutischen verwendung.
BRPI0812875A2 (pt) " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ".
DE60025347D1 (de) Methoden zur vohersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
EP4283304A2 (de) Verfahren zum nachweis von anti-leptin-neutralisierenden antikörpern
WO2007098297A3 (en) Method for diagnosing and treating kidney cancer
ATE481644T1 (de) Prognose des verlaufs einer krebserkrankung
WO2009043848A3 (en) Use of the serological assay of the cytokine b-lymphocyte stimulator (blys) for the diagnosis, prognosis and the screening of therapeutic efficacy in immune-related diseases including organ-specific autoimmune diseases and transfusion reactions
DE69821246D1 (de) Testverfahren für collagenpeptid
ATE366420T1 (de) Kit und verfahren zur bestimmung von protein esm- 1
WO2005019831B1 (en) Methods for reducing complexity of a sample using small epitope antibodies
DE502006005889D1 (de) Immunoassay zur simultanen immunchemischen bestimmung eines analyten (antigen) und eines gegen den analyten gerichteten therapieantikörpers in proben (recovery immunoassay)
NO20052870D0 (no) Immunoanalysemetode og sett for anvendelse derav
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties